Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hsu

Showing results (751-760 of 761) with videos related to

Pageof 77
Sort By:
The Journal of Rheumatology|October 3, 2018
Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS RegistryVivien M Hsu, Lorinda Chung, Laura K Hummers, et al.
Arthritis and Rheumatism|May 1, 2007
Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung studyDinesh Khanna, Xiaohong Yan, Donald P Tashkin, et al.
The New England Journal of Medicine|June 23, 2006
Cyclophosphamide versus placebo in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
American Journal of Respiratory and Critical Care Medicine|August 25, 2007
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
ACR Open Rheumatology|November 26, 2025
Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis-Related Interstitial Lung Disease (Scleroderma Lung Study III): An Investigator-Initiated, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 TrialDinesh Khanna, Cathie Spino, Donald P Tashkin, et al.
Annals of the Rheumatic Diseases|April 11, 2019
Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort studyMuriel Elhai, Marouane Boubaya, Oliver Distler, et al.
The Lancet. Respiratory Medicine|July 30, 2016
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trialDonald P Tashkin, Michael D Roth, Philip J Clements, et al.
CMAJ Open|March 10, 2021
Characteristics and outcomes of patients with COVID-19 admitted to hospital and intensive care in the first phase of the pandemic in Canada: a national cohort studySrinivas Murthy, Patrick M Archambault, Anika Atique, et al.
Arthritis and Rheumatism|October 15, 2013
2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiativeFrank van den Hoogen, Dinesh Khanna, Jaap Fransen, et al.
Annals of the Rheumatic Diseases|October 5, 2013
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiativeFrank van den Hoogen, Dinesh Khanna, Jaap Fransen, et al.
Pageof 77

Showing results (751-760 of 761) with videos related to

Sort By:
Pageof 77
The Journal of Rheumatology|October 3, 2018
Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS RegistryVivien M Hsu, Lorinda Chung, Laura K Hummers, et al.
Arthritis and Rheumatism|May 1, 2007
Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung studyDinesh Khanna, Xiaohong Yan, Donald P Tashkin, et al.
The New England Journal of Medicine|June 23, 2006
Cyclophosphamide versus placebo in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
American Journal of Respiratory and Critical Care Medicine|August 25, 2007
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
ACR Open Rheumatology|November 26, 2025
Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis-Related Interstitial Lung Disease (Scleroderma Lung Study III): An Investigator-Initiated, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 TrialDinesh Khanna, Cathie Spino, Donald P Tashkin, et al.
Annals of the Rheumatic Diseases|April 11, 2019
Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort studyMuriel Elhai, Marouane Boubaya, Oliver Distler, et al.
The Lancet. Respiratory Medicine|July 30, 2016
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trialDonald P Tashkin, Michael D Roth, Philip J Clements, et al.
CMAJ Open|March 10, 2021
Characteristics and outcomes of patients with COVID-19 admitted to hospital and intensive care in the first phase of the pandemic in Canada: a national cohort studySrinivas Murthy, Patrick M Archambault, Anika Atique, et al.
Arthritis and Rheumatism|October 15, 2013
2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiativeFrank van den Hoogen, Dinesh Khanna, Jaap Fransen, et al.
Annals of the Rheumatic Diseases|October 5, 2013
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiativeFrank van den Hoogen, Dinesh Khanna, Jaap Fransen, et al.
Pageof 77